Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimer’s disease
Abstract The specific amyloid-beta (Aβ) species or other amyloid-precursor protein cleavage products that are most directly related to human neurodegeneration and clinical dementia of the Alzheimer’s type have not yet been directly identified. Without a clear understanding of the most relevant speci...
Main Authors: | David L. Brody, Hao Jiang, Norelle Wildburger, Thomas J. Esparza |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-08-01
|
Series: | Alzheimer’s Research & Therapy |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13195-017-0293-3 |
Similar Items
-
Label-free vibrational imaging of different Aβ plaque types in Alzheimer’s disease reveals sequential events in plaque development
by: Dominik Röhr, et al.
Published: (2020-12-01) -
Antibody Fragments as Tools for Elucidating Structure-Toxicity Relationships and for Diagnostic/Therapeutic Targeting of Neurotoxic Amyloid Oligomers
by: André L. B. Bitencourt, et al.
Published: (2020-11-01) -
Probing the Occurrence of Soluble Oligomers through Amyloid Aggregation Scaling Laws
by: Alexandra Silva, et al.
Published: (2018-10-01) -
Three Structural Features of Functional Food Components and Herbal Medicine with Amyloid β42 Anti-Aggregation Properties
by: Kazuma Murakami, et al.
Published: (2019-06-01) -
L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer's disease
by: Thimmappa S. Anekonda, et al.
Published: (2011-01-01)